Bristol-Myers Squibb and Starboard Value square off over Celgene deal
March 19, 2019 at 09:45 AM EDT
Activist investor says Bristol-Myers' Celgene deal "is ill-advised and could destroy substantial value for shareholders"; Bristol-Myers argues the deal "is a financially and strategically compelling transaction."
